secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001193125-26-005418
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint provides 2026 clinical milestones; ~$300M cash; wet AMD data mid-2026
------------------------------------------------------------------------------

- Phase 3 LUGANO (432 pts) wet AMD top-line data expected mid-2026; LUCIA (475 pts) data to follow.
- Phase 3 DME program (COMO/CAPRI) first patient dosing expected Q1 2026; ~240 pts each.
- Preliminary cash & investments ~$300M at Dec 31, 2025; runway into Q4 2027.
- DSMC second review recommended continuation of Phase 3 program with no protocol changes.
- Presenting at J.P. Morgan Healthcare Conference on Jan 13, 2026 at 7:30 a.m. PT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526005418/0001193125-26-005418-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526005418/eypt-20260107.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-005418

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer